Zhongdong Shi

Company: Frontera Therapeutics

Job title: Vice President & Head of Research & Development

Seminars:

Engineering Payload to Increase Expression Durability & Lower Doses 3:30 pm

Highlighting current developments and challenges in AAV gene therapy for Hemophilia A Emphasizing how engineering the FVIII protein to generate hyperfunctional mutants could enhance expression durability and improve therapeutic efficacy Demonstrating an efficient approach to generate hyperfunctional transgenes, enabling lower therapeutic doses and improved durability compared to firstgeneration AAV gene therapiesRead more

day: Conference Day One